Myokardia Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Myokardia

Access the complete profile.

Myokardia Fast Facts

Revenue	$100 - $500 million    See Exact Annual Revenue
Employees	N/AExact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Address	333 Allerton Avenue South San Francisco, CA 94080

Myokardia's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Myokardia's annual revenues are $100 - $500 million (see exact revenue data)
• What industry is the company in?
  • Myokardia is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Myokardia is a publicly traded company on NMS using the ticker symbol MYOK. Detailed information on company financials and operating reports can be found here: NMS: MYOK

Myokardia Annual Revenue and Growth Rate

Myokardia	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$100 - $500 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Myokardia's revenues are gauged from an analysis of company filings.

Investor Activity

Myokardia has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date	Investors	Percent Raised	Target Size
April 30, 2015	9	100%	$46 MM
Complete list of funding rounds and total amounts in the Company Report

Trademark Applications

Trademark applications show the products and services that Myokardia is developing and marketing. Myokardia doesn't have any recent trademark applications, indicating Myokardia is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
MY CAMZYOS PATIENT SUPPORT Health care services, namely, providing information to physicians, health care professionals and patients on the topic of health issues and health awareness; Charitable services, namely, patient assistance program to provide drugs and medical services at a reduced cost to low-income patients without prescription drug coverage or health insurance coverage	11/05/2021
ETUZMI Pharmaceutical and biological preparations for human use	05/11/2021
EVMYGO Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; monoclonal antibodies for therapeutic use for treating viral infections, inflammatory diseases, cardiovascular diseases, auto-immune diseases, blood diseases, and cancers	05/11/2021

See all trademarks and details in the Full Report.

Market Share of Myokardia's Largest Competitors

A competitive analysis shows these companies are in the same general field as Myokardia, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Myokardia. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
GENENTECH	South San Francisco, CA	100
IGM BIOSCIENCES	Mountain View, CA	1
AKASA	South San Francisco, CA	1
MYOKARDIA	South San Francisco, CA	1
KRIYA THERAPEUTICS	Redwood City, CA	1
EPICRISPR BIOTECHNOLOGIES	South San Francisco, CA	1

Future Competition: Myokardia's Fastest Growing Competitors

These companies are in the same general field as Myokardia and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)